362 results on '"Lenting, Peter J."'
Search Results
2. Fitusiran reduces bleeding in factor X–deficient mice
3. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis
4. How unique structural adaptations support and coordinate the complex function of von Willebrand factor
5. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor
6. Angiopoietin-2 binds to multiple interactive sites within von Willebrand factor
7. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy
8. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models
9. Antithrombin lowering in hemophilia: a closer look at fitusiran
10. A reactive center loop–based prediction platform to enhance the design of therapeutic SERPINs
11. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD
12. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab
13. Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S
14. Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells
15. PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space.
16. Genotype-Dependent Response to Desmopressin in Hemophilia A and Proposal of a Predictive Response Score.
17. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis
18. Mortality, cardiac and cerebral damages reduction by IL-1 inhibition in a murine model of TTP
19. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID‐19
20. The Role of Platelets and von Willebrand Factor in the Procoagulant Phenotype of Inflammatory Bowel Disease.
21. Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications
22. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation
23. Laboratory monitoring of hemophilia A treatments: new challenges
24. Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc
25. The role of platelets and von Willebrand factor in the procoagulant phenotype of inflammatory bowel disease
26. A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor
27. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
28. von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week
29. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor
30. Shear Forces Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia
31. Real-Time Monitoring of von Willebrand Factor in the Catheterization Laboratory: The Seatbelt of Mini-Invasive Transcatheter Aortic Valve Replacement?
32. Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support
33. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
34. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
35. IdeS, a new option to optimize the management of patients with hemophilia A on emicizumab
36. Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19
37. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
38. Author Correction: Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
39. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A
40. Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X
41. VON WILLEBRAND FACTOR: FROM FIGURANT TO MAIN CHARACTER IN THE SCENE OF INFLAMMATION
42. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends
43. A nanobody against the von Willebrand factor A3-domain detects ADAMTS13-induced proteolysis in congenital & acquired VWD
44. A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a
45. P.31 Von Willebrand Factor Induces Vascular Smooth Muscle Cell Proliferation and Migration Through Low Density Lipoprotein-Related Receptor Protein 4 and αvβ3 Integrin
46. Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort
47. von Willebrand Factor for Aortic Valve Intervention: From Bench to Real-Time Bedside Assessment
48. Abstract 19793: Pulsatility Modulates the Acquired Von Willebrand Factor Defect Related to Mechanical Circulatory Support Devices
49. Transient von Willebrand factor‐mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice
50. Towards novel treatment options in von Willebrand disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.